Skip to content

Up-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's disease

Up-down sequential testing of propofol - induced half-effective dose ( ed50 ) in patients with Parkinson's disease and non - Parkinson's disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014542
Enrollment
Unknown
Registered
2018-01-20
Start date
2018-01-22
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Interventions

PD group:propofol
NPD group:propofol

Sponsors

Xuanwu Hospital of CCMU
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. ASA grades I-II; 2. Age 18 - 65 years; 3. BMI< 35; 4. No severe respiratory and circulatory diseases; 5. Patients signed informed consent, and approved by the hospital ethics Committee, etc. Pd: diagnosis of Parkinson's disease during hospitalization, selective DBS treatment, in line with surgical indications (excluding dementia, etc.);

Exclusion criteria

Exclusion criteria: 1. Patients allergic to propofol; 2. Lipids metabolism disorder; 3. Alcoholics; 4. Patients with bis of less than 80 when entering operating room; 5. After induction, the mean arterial pressure decreased by more than 20 % 6. Patients with severe respiratory and circulatory diseases.

Design outcomes

Primary

MeasureTime frame
BIS value;

Secondary

MeasureTime frame
age;gender;Body Mass Index;state of consciousness before operation;Blood pressure;MAP;HR;SpO2;PET CO2;temperature;ASA status;NYHA functional class;MET class;complication of other systems;length of surgery;infusion volume;lost volume;whether extubation;postoperative consciousness;postoperative whereabouts;hospital stay;

Countries

China

Contacts

Public ContactZHAO LEI

Xuanwu Hospital of CCMU

zhaoalei@sina.com+86 13811035886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026